Valuation : enGene Therapeutics Inc.

Market Cap 119M 102M 96.21M 87.65M 164M 11.34B 165M 1.15B 441M 5.75B 445M 436M 18.26B P/E 2026 *
-0.98x
P/E 2027 * -1.14x
Enterprise Value -92.68M -79.7M -75.2M -68.51M -128M -8.86B -129M -896M -345M -4.49B -348M -340M -14.28B EV / Sales 2026 *
-
EV / Sales 2027 * -4.55x
Free-Float
99.9%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : enGene Therapeutics Inc.

1 day-4.32%
1 week-3.28%
Current month-3.80%
1 month+1.14%
3 months+10.62%
6 months-74.50%
Current year-80.40%
1 week 1.76
Extreme 1.76
1.94
1 month 1.66
Extreme 1.66
1.95
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
47.17
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 22/07/2024
Chief Tech/Sci/R&D Officer 55 24/04/2023
Director of Finance/CFO 48 16/07/2026
Director TitleAgeSince
Director/Board Member 57 08/08/2023
Director/Board Member 66 18/12/2023
Director/Board Member 66 15/05/2024
Date Insider Type Main position Quantity % Market Cap. Importance
16/7/26 Other

Interim Chief Business Officer

75,000 0.1120%
16/7/26 Other

Chief Financial Officer

0 0%
16/7/26 Other

Chief Financial Officer

170,800 0.2550%
Change 5-day change 1-year change 3-year change Capi.($)
-4.32%-3.28%-71.86%-83.76% 119M
-0.25%-1.36%+44.08%+102.76% 68.24B
+0.05%-4.16%+30.79%+74.17% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
+0.12%-3.88%+14.25%-19.71% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average -1.37%-3.30%+27.95%+145.77% 27.28B
Weighted average by Cap. -0.71%-3.10%+35.36%+136.58%

Financials

2026 *2027 *
Net sales - 6.17M 5.31M 5.01M 4.56M 8.53M 590M 8.6M 59.63M 22.95M 299M 23.17M 22.66M 950M
Net income -125M -107M -101M -92.22M -172M -11.93B -174M -1.21B -464M -6.05B -468M -458M -19.22B -122M -105M -98.8M -90.01M -168M -11.64B -170M -1.18B -453M -5.9B -457M -447M -18.76B
Net Debt -211M -182M -171M -156M -292M -20.2B -295M -2.04B -786M -10.24B -793M -776M -32.54B -147M -126M -119M -108M -203M -14.02B -204M -1.42B -545M -7.11B -551M -539M -22.59B
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
-
Date Price Change Volume
10/09/26 US$1.770 -4.32% 565,327
09/09/26 US$1.850 -3.65% 486,375
08/09/26 US$1.920 +5.49% 1,508,314
04/09/26 US$1.820 -0.55% 412,684
03/09/26 US$1.830 -3.17% 634,651
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
1.770USD
Average target price
3.286USD
Spread / Average Target
+85.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ENGN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!